These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36494344)

  • 1. A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration.
    Ma H; Zhang X; Zeng W; Zhou J; Chi X; Chen S; Zheng P; Wang M; Wu Y; Zhao D; Gong F; Lin H; Sun H; Yu C; Shi Z; Hu X; Zhang H; Jin T; Chiu S
    Cell Discov; 2022 Dec; 8(1):132. PubMed ID: 36494344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron.
    Ma H; Zhang X; Zheng P; Dube PH; Zeng W; Chen S; Cheng Q; Yang Y; Wu Y; Zhou J; Hu X; Xiang Y; Zhang H; Chiu S; Jin T
    Cell Res; 2022 Sep; 32(9):831-842. PubMed ID: 35906408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies.
    Wang Y; Zhang X; Ma Y; Wang Y; Zhan W; Zheng Q; Zhang M; Ji P; Liu M; Liu Q; Sun T; Zhu T; Wen Y; Sun L; Zhao J; Wu F; Chen Z; Huang J
    Cell Discov; 2022 Oct; 8(1):104. PubMed ID: 36207299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants.
    Li Q; Humphries F; Girardin RC; Wallace A; Ejemel M; Amcheslavsky A; McMahon CT; Schiller ZA; Ma Z; Cruz J; Dupuis AP; Payne AF; Maryam A; Yilmaz NK; McDonough KA; Pierce BG; Schiffer CA; Kruse AC; Klempner MS; Cavacini LA; Fitzgerald KA; Wang Y
    Front Immunol; 2022; 13():995412. PubMed ID: 36172366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1.
    Wang J; Shi B; Chen H; Yu M; Wang P; Qian Z; Hu K; Wang J
    Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode.
    Zhao D; Liu L; Liu X; Zhang J; Yin Y; Luan L; Jiang D; Yang X; Li L; Xiong H; Xing D; Zheng Q; Xia N; Tao Y; Li S; Huang H
    J Nanobiotechnology; 2022 Sep; 20(1):411. PubMed ID: 36109732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5.
    Wang Y; Yan A; Song D; Dong C; Rao M; Gao Y; Qi R; Ma X; Wang Q; Xu H; Liu H; Han J; Duan M; Liu S; Yu X; Zong M; Feng J; Jiao J; Zhang H; Li M; Yu B; Wang Y; Meng F; Ni X; Li Y; Shen Z; Sun B; Shao X; Zhao H; Zhao Y; Li R; Zhang Y; Du G; Lu J; You C; Jiang H; Zhang L; Wang L; Dou C; Liu Z; Zhao J
    Cell Discov; 2023 Jan; 9(1):3. PubMed ID: 36609558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
    Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
    Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An engineered bispecific nanobody in tetrameric secretory IgA format confers broad neutralization against SARS-CoV-1&2 and most variants.
    Zeng W; Jia X; Chi X; Zhang X; Li E; Wu Y; Liu Y; Han J; Ni K; Ye X; Hu X; Ma H; Yu C; Chiu S; Jin T
    Int J Biol Macromol; 2023 Dec; 253(Pt 3):126817. PubMed ID: 37690653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratracheal trimerized nanobody cocktail administration suppresses weight loss and prolongs survival of SARS-CoV-2 infected mice.
    Nagata K; Utsumi D; Asaka MN; Maeda R; Shirakawa K; Kazuma Y; Nomura R; Horisawa Y; Yanagida Y; Kawai Y; Sato K; Yamaoka Y; Miyakawa K; Ryo A; Yasutomi Y; Imura A; Takaori-Kondo A
    Commun Med (Lond); 2022 Nov; 2(1):152. PubMed ID: 36435945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of ISH0339, a tetravalent broadly neutralizing bispecific antibody against SARS-CoV-2 with long-term protection.
    Yang H; Chen Y; Jiang D; Feng X; Xu Y; Wei J; Zou Q; Yang Q; Chen J; Jiang X; Qin C; Huang Z; Wu C; Zhou Y; Li M; Yin L
    Antib Ther; 2023 Apr; 6(2):97-107. PubMed ID: 37077474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel nanobody broadly neutralizes SARS-CoV-2 via induction of spike trimer dimers conformation.
    Yang Y; Zhang J; Zhang S; Zhang C; Shen C; Song S; Wang Y; Peng Y; Gong X; Dai J; Xie C; Khrustaleva TA; Khrustalev VV; Huo Y; Lu D; Yao D; Zhao J; Liu Y; Lu H
    Exploration (Beijing); 2024 Jun; 4(3):20230086. PubMed ID: 38939869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses, including all major Omicron strains.
    Yao H; Wang H; Zhang Z; Lu Y; Zhang Z; Zhang Y; Xiong X; Wang Y; Wang Z; Yang H; Zhao J; Xu W
    MedComm (2020); 2023 Dec; 4(6):e397. PubMed ID: 37901798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.
    Wu X; Cheng L; Fu M; Huang B; Zhu L; Xu S; Shi H; Zhang D; Yuan H; Nawaz W; Yang P; Hu Q; Liu Y; Wu Z
    Cell Rep; 2021 Oct; 37(3):109869. PubMed ID: 34644535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
    Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X
    Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
    Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
    mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
    Westendorf K; Žentelis S; Wang L; Foster D; Vaillancourt P; Wiggin M; Lovett E; van der Lee R; Hendle J; Pustilnik A; Sauder JM; Kraft L; Hwang Y; Siegel RW; Chen J; Heinz BA; Higgs RE; Kallewaard NL; Jepson K; Goya R; Smith MA; Collins DW; Pellacani D; Xiang P; de Puyraimond V; Ricicova M; Devorkin L; Pritchard C; O'Neill A; Dalal K; Panwar P; Dhupar H; Garces FA; Cohen CA; Dye JM; Huie KE; Badger CV; Kobasa D; Audet J; Freitas JJ; Hassanali S; Hughes I; Munoz L; Palma HC; Ramamurthy B; Cross RW; Geisbert TW; Menacherry V; Lokugamage K; Borisevich V; Lanz I; Anderson L; Sipahimalani P; Corbett KS; Yang ES; Zhang Y; Shi W; Zhou T; Choe M; Misasi J; Kwong PD; Sullivan NJ; Graham BS; Fernandez TL; Hansen CL; Falconer E; Mascola JR; Jones BE; Barnhart BC
    bioRxiv; 2022 Mar; ():. PubMed ID: 33972947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.